The Next Frontier in Cancer Care

Value has become a central topic in any debate regarding cancer care in Greece and abroad, for a simple reason: reality has caught up with us. Costs and treatment innovations are conflicting realities that force the oncology community to adopt value-based solutions to a system in crisis. On one side, the pace of innovation in oncology is tremendous and unprecedented: newly approved drugs abound; precision oncology and immunotherapy are gradually becoming a reality; and patients are having access to an increasing number of treatment options that help them live longer with better quality of life. On the other side, the costs to treat cancer are astronomical and continue to increase, threatening our own ability to provide cancer care and causing financial harm to patients.

Scientific Committee

President

Odysseas Zoras, MD, PhD FACS, Rector of the University of Crete, Professor in Surgical Oncology, University of Crete, Medical School, Head of the Department of Surgical Oncology, University Hospital of Heraklion, Member of the BoD of the European Society of Surgical Oncology (ESSO), Past President of the Hellenic Society of Surgical Oncology (HSSO)

Honorary President

Othon Iliopoulos, Associate Professor of Medicine, Harvard Medical School, Member of the Hellenic National Council of Research and Innovation (ΕΣΕΚ)

Members

Ioannis Boukovinas, MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, “Bioclinic”, Thessaloniki, Greece, President of the Hellenic Society of Medical Oncology (HeSMO)
Maria Gazouli, PhD, Associate Professor of Molecular Biology, Medical School, National and Kapodistrian University of Athens
Zoe Grammatoglou, President of the Hellenic Association of Cancer Patients K.E.F.I. of Athens
George Kapetanakis, Secretary, The Hellenic Cancer Federation – ELLOK
Paris Kosmidis, Medical Oncologist at Hygeia Hospital, past ESMO President
Zenia Saridaki-Zoras, MD, PhD Medical Oncologist, Scientific Director of the Oncology Department “Asklepios”, Member of the Board of Directors of the Hellenic Society of Medical Oncology
Konstantinos N. Syrigos, MD, PhD, FCCP, Professor of Medicine & Medical Oncology, Head, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, Adj. Professor of Medicine, Pittsburgh School of Medicine, USA, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA

Conference’s Scope

The conference, now in its fourth year, is a forum for discussion for government representatives, academic society, physicians, patients, researchers, and pharmaceutical industry executives, to discuss innovative therapeutic approaches and cost-effective measures to the benefit of healthcare system and patients. The scope of the conference is to explore opportunities for greater multi-stakeholder cooperation and a more integrated approach to cancer care as key drivers to deliver sustainable and high-value care for patients. Best practices at a national and international level will contribute to the dialogue aiming at significantly improving cancer patient outcomes, fostering innovative research approaches, intensifying cancer prevention research efforts, and reducing the financial burden targeted to this disease.

This year the special theme of the conference is the next frontier in cancer care that aims to showcase the most innovative methods of treatment, while at the same time confronting the urgency to balance the delivery of high quality cancer care with costs. Cancer & Personalized Medicine Conference will offer a platform to discuss new models of care delivery and reimbursement that emphasize value.

Key Issues

Cancer Policies and the Cost of Precenting, Researching and Treating Cancer
Innovation in Cancer Research & Treatment
Personalised and Targeted Therapies & the Use of Biomarkers

Who should attend

Government representatives
National health system regulators and administrators
Academic Society
Consultants
Researchers
Radiologists
Chemotherapists
Pathologists
Patient Advocates and Patient Groups
Healthcare Industry representatives (Pharmaceutical Companies, Medical Devices Manufacturing Companies, Diagnostics Companies)
Students
Journalists

Keynote Speakers

A. John Iafrate Dr. Iafrate is a Professor of Pathology at Harvard Medical School and is Director of the Center for Integrated Diagnostics (CID), a clinical laboratory for molecular diagnostics and newly appointed Vice Chair of Academic Affairs at the Massachusetts General Hospital (MGH).

Stephen Palmer Stephen Palmer is a Professor and Deputy Director of TEEHTA. He has worked in economic evaluation for over 15 years in areas including pharmaceuticals, cardiology, cancer, mental health, diagnostic and screening programmes and policy. He has extensive experience of health economic evaluation, regulatory and reimbursement processes.

Luca Sangiorgi He is Head of Department of Medical Genetics and Coordinator of Rare Disease Centre at Rizzoli Orthopaedic Institute, Bologna, and Contract professor of Clinical Genetics of Bologna University.

Speakers & Coordinators

Costas Fotakis

Christos Antonopoulos, MD, PhD, MBA, Director, Oncology Business Unit , AstraZeneca Pharmaceuticals Greece
Kathy Apostolidis, President - Hellenic Cancer Federation-ELL.O.K., Vice President of ECPC-European Cancer Patient Coalition
Ioannis Boukovinas, MD, PhD, Medical Oncologist, Head of Oncology Unit, “Bioclinic”, Thessaloniki, Greece, President of the Hellenic Society of Medical Oncology (HeSMO)
Dr Giorgos Chourdakis, Director, Research and Innovation Sector, Ministry of Education, Research and Religious Affairs
Εvangelos Filopoulos, President, Hellenic Cancer Society, Surgeon, Director of the Breast Cancer Clinic "Agios Savvas"
George Galanopoulos, MD, Medical Director, Gilead Sciences Hellas
Maria Gazouli, PhD Associate Professor of Molecular Biology, Medical School, National & Kapodistrian University of Athens
Othon Iliopoulos, Associate Professor of Medicine, Harvard Medical School, Member of the Hellenic National Council of Research and Innovation (ΕΣΕΚ)
Tomasz Kluszczynski, Senior Principal, IQVIA
Christos Kroupis, Assistant Professor of Clinical Biochemistry and Molecular Diagnostics, Attikon University General Hospital, National and Kapodistrian University of Athens, Lead Assessor in the National Accreditation System of Greece (E.SY.D.), National Representative, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Eleni Linardou, MD PhD, PhD Imperial College University of London, Medical Oncologist, Director - Oncology Unit, Metropolitan Hospital, Athens
Ioanna Michalopoulou , Lawyer, LL.M. Managing Partner at Michalopoulou & Associates Law Group
Ioannis Mountzios, MSc, PhD, Medical Oncologist, 251 Airforce General Hospital, 2nd Oncology Department, Henry Dunant Hospital Center
Makis Papataxiarchis, President PhRMA Innovation Forum (PIF), Chairman, AMCHAM Pharma Committee
George Pentheroudakis, MD Associate Professor of Oncology, Department of Medical Oncology, Medical School, University of Ioannina
Vasilis Ramfidis MD, MSc, Medical Oncologist, 3rd Department of Medicine Sotiria General Hospital, 251 General Air Force Hospital, Athens, Greece
Zenia Saridaki-Zoras, MD, PhD Medical Oncologist, Scientific Director of the Oncology Department “Asklepios”, Member of the Board of Directors of the Hellenic Society of Medical Oncology
Petros Sfikakis, President of Medical School, University of Athens, Professor of Internal Medicine & Rheumatology, Medical School, National and Kapodistrian University of Athens
Konstantinos N. Syrigos, MD, PhD, FCCP, Professor of Medicine & Medical Oncology, Head, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, Adj. Professor of Medicine, Pittsburgh School of Medicine, USA, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA